Geneviève Amaral
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Geneviève Amaral has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Calvin Ka-Fung Lo
The University of British Columbia
4 shared publications - Ahmad Aloufi
Antimicrobial Stewardship Program, Providence Health Care, Vancouver, BC, Canada
3 shared publications - Hasan Hamze
Department of Pathology and Laboratory Medicine The University of British Columbia 2211 Wesbrook Mall, Vancouver, BC V6T 1Z7, Canada
3 shared publications - Aleksandra Stefanovic
Department of Pathology and Laboratory Medicine, University of British Columbia , Vancouver, British Columbia
2 shared publications - Christopher F. Lowe
University of British Columbia
2 shared publications - Gordon Ritchie
Providence Health Care
2 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (6) , e0370325
Performance of the Xpert Xpress Strep A for detection of Streptococcus pyogenes from pediatric pleural fluids
In Canada, Group A streptococcal (GAS) pneumonia is a severe invasive GAS (iGAS) condition reportable to public health for consideration of chemoprophylaxis for close contacts. It is often complicated by parapneumonic effusion. Sterile site culture from pleural fluid is the diagnostic gold standard but is insensitive, particularly given that many patients will have received antibiotics prior to sample collection. Xpert Xpress Strep A (Cepheid, Sunnyvale, CA) is a quantitative real-time (qPCR) assay targeting the speB gene designed to rapidly detect Streptococcus pyogenes from throat swabs. We evaluated its performance compared to bacterial culture for pediatric pleural fluids. A convenience sample of 36 specimens (21 positive, 15 negative) obtained January 2023 to April 2025 was included. Results were compared to a composite reference standard consisting of positive culture and a laboratory-developed (LD) qPCR targeting the spy1258 gene. Limit of detection (LoD) for LD qPCR was determined by testing a dilution series of negative pleural fluids spiked with a predefined concentration (copies/mL) of S. pyogenes ATCC 19615 and using 95% hit rate analysis for Xpert. All 21 positive samples tested (100%) were detected by Xpert and the composite reference standard, while only 8/21 (38%) were culture positive. Xpert demonstrated 100% positive percent agreement, negative percent agreement, and overall categorical agreement (ĸ = 1) with the composite reference standard and individual LD qPCR. There was 64% categorical agreement between Xpert and culture alone (ĸ = 0.3). Xpert was more sensitive for detecting S. pyogenes than culture from pleural fluid. Faster turnaround time shortened the window to optimal therapy, supporting its diagnostic utility. IMPORTANCE: Group A streptococcal (GAS) pneumonia, a predominant pathogen in pediatric complicated pneumonia and a severe form of invasive GAS infection, requires prompt diagnosis, both for clinical patient management and identification of close contacts for public health evaluation. Pleural effusion is a common complication. Recovery of GAS from a sterile site like pleural fluid is a key criterion to categorize disease as invasive. However, microbiological yield is often low and may be improved by applying molecular diagnostic techniques. In our study, we demonstrate the utility of Xpert Xpress Strep A for Cepheid GeneXpert for rapid detection of GAS in pediatric pleural fluids. We demonstrated excellent sensitivity with Xpert detecting all 21/21 (100%) positive specimens, compared to culture alone, which was only positive for 8/21 (38%).
- 2 June 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (6) , e0370325
Open AccessPerformance of the Xpert Xpress Strep A for detection of Streptococcus pyogenes from pediatric pleural fluids
In Canada, Group A streptococcal (GAS) pneumonia is a severe invasive GAS (iGAS) condition reportable to public health for consideration of chemoprophylaxis for close contacts. It is often complicated by parapneumonic effusion. Sterile site culture from pleural fluid is the diagnostic gold standard but is insensitive, particularly given that many patients will have received antibiotics prior to sample collection. Xpert Xpress Strep A (Cepheid, Sunnyvale, CA) is a quantitative real-time (qPCR) assay targeting the speB gene designed to rapidly detect Streptococcus pyogenes from throat swabs. We evaluated its performance compared to bacterial culture for pediatric pleural fluids. A convenience sample of 36 specimens (21 positive, 15 negative) obtained January 2023 to April 2025 was included. Results were compared to a composite reference standard consisting of positive culture and a laboratory-developed (LD) qPCR targeting the spy1258 gene. Limit of detection (LoD) for LD qPCR was determined by testing a dilution series of negative pleural fluids spiked with a predefined concentration (copies/mL) of S. pyogenes ATCC 19615 and using 95% hit rate analysis for Xpert. All 21 positive samples tested (100%) were detected by Xpert and the composite reference standard, while only 8/21 (38%) were culture positive. Xpert demonstrated 100% positive percent agreement, negative percent agreement, and overall categorical agreement (ĸ = 1) with the composite reference standard and individual LD qPCR. There was 64% categorical agreement between Xpert and culture alone (ĸ = 0.3). Xpert was more sensitive for detecting S. pyogenes than culture from pleural fluid. Faster turnaround time shortened the window to optimal therapy, supporting its diagnostic utility. IMPORTANCE: Group A streptococcal (GAS) pneumonia, a predominant pathogen in pediatric complicated pneumonia and a severe form of invasive GAS infection, requires prompt diagnosis, both for clinical patient management and identification of close contacts for public health evaluation. Pleural effusion is a common complication. Recovery of GAS from a sterile site like pleural fluid is a key criterion to categorize disease as invasive. However, microbiological yield is often low and may be improved by applying molecular diagnostic techniques. In our study, we demonstrate the utility of Xpert Xpress Strep A for Cepheid GeneXpert for rapid detection of GAS in pediatric pleural fluids. We demonstrated excellent sensitivity with Xpert detecting all 21/21 (100%) positive specimens, compared to culture alone, which was only positive for 8/21 (38%).
- Open Access
- 1 April 2026
- Published by Microbiology Society in Access Microbiology
- Vol. 8 (4) , 001122.v3
Antimicrobial susceptibility and distribution trends among inducible AmpC-producing Enterobacterales at a regional health authority in British Columbia: a 5-year retrospective review
Introduction. Existing literature supports using cefepime as a carbapenem-sparing agent to treat AmpC-producing Enterobacterales infections. To characterize existing susceptibility trends, we conducted a 5-year retrospective study assessing MIC distributions for ceftriaxone, cefepime, piperacillin–tazobactam and meropenem across Vancouver Island Health Authority (Vancouver Island, British Columbia, Canada). Methods. MIC data for AmpC isolates between November 2019 and October 2024 were retrieved (BD EpiCenter™). Blood cultures, invasive specimens, urine and miscellaneous samples (e.g. respiratory and wounds) were included; we excluded surveillance specimens. MIC values were interpreted based upon CLSI M100-E34 breakpoints (Table 2a-1). Descriptive statistics were computed and compared between moderate-risk AmpC (MRAC) inducers versus low-risk AmpC (LRAC) inducers. Results. A total of 5,631 isolates were analysed, with 3,778 (67.1%) identified as MRAC. Across all organisms, susceptibility rates for ceftriaxone, piperacillin–tazobactam, cefepime and meropenem were 82.0%, 87.0%, 95.4% and 98.7%, respectively. Compared to LRAC, MRAC organisms demonstrated lower susceptibility to ceftriaxone (76.0% versus 94.2%) and piperacillin–tazobactam (81.3% versus 98.6%). Cefepime and meropenem demonstrated similar susceptibility rates between LRAC and MRAC. MIC 90 for cefepime was 1 µg ml −1 for all species except Enterobacter cloacae (MIC 90 4 µg ml −1 ). Conclusion. Between 2019 and 2024, 95.4% of our isolates demonstrated susceptibility to cefepime within our local health authority. Further research will correlate patient outcomes and establish MIC thresholds to guide routine testing and clinical use of cefepime.
- 1 April 2026
- Published by Microbiology Society in Access Microbiology
- Vol. 8 (4) , 001122.v3
Open AccessAntimicrobial susceptibility and distribution trends among inducible AmpC-producing Enterobacterales at a regional health authority in British Columbia: a 5-year retrospective review
Introduction. Existing literature supports using cefepime as a carbapenem-sparing agent to treat AmpC-producing Enterobacterales infections. To characterize existing susceptibility trends, we conducted a 5-year retrospective study assessing MIC distributions for ceftriaxone, cefepime, piperacillin–tazobactam and meropenem across Vancouver Island Health Authority (Vancouver Island, British Columbia, Canada). Methods. MIC data for AmpC isolates between November 2019 and October 2024 were retrieved (BD EpiCenter™). Blood cultures, invasive specimens, urine and miscellaneous samples (e.g. respiratory and wounds) were included; we excluded surveillance specimens. MIC values were interpreted based upon CLSI M100-E34 breakpoints (Table 2a-1). Descriptive statistics were computed and compared between moderate-risk AmpC (MRAC) inducers versus low-risk AmpC (LRAC) inducers. Results. A total of 5,631 isolates were analysed, with 3,778 (67.1%) identified as MRAC. Across all organisms, susceptibility rates for ceftriaxone, piperacillin–tazobactam, cefepime and meropenem were 82.0%, 87.0%, 95.4% and 98.7%, respectively. Compared to LRAC, MRAC organisms demonstrated lower susceptibility to ceftriaxone (76.0% versus 94.2%) and piperacillin–tazobactam (81.3% versus 98.6%). Cefepime and meropenem demonstrated similar susceptibility rates between LRAC and MRAC. MIC 90 for cefepime was 1 µg ml −1 for all species except Enterobacter cloacae (MIC 90 4 µg ml −1 ). Conclusion. Between 2019 and 2024, 95.4% of our isolates demonstrated susceptibility to cefepime within our local health authority. Further research will correlate patient outcomes and establish MIC thresholds to guide routine testing and clinical use of cefepime.
- Open Access
- 11 March 2026
- Published by Microbiology Society
- p. 001122.v2
Antimicrobial susceptibility and distribution trends among inducible AmpC-producing Enterobacterales at a regional health authority in British Columbia: a 5-year retrospective review
Introduction: Existing literature supports using cefepime as a carbapenem-sparing agent to treat AmpC-producing Enterobacterales infections. To characterize existing susceptibility trends, we conducted a 5-year retrospective study assessing minimum inhibitory concentration (MIC) distributions for ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem across Vancouver Island Health Authority (Vancouver Island, British Columbia, Canada). Methods: MIC data for AmpC isolates between November 2019 to October 2024 were retrieved (BD Epicenter™). Blood cultures, invasive specimens, urine and miscellaneous samples (e.g., respiratory, wounds) were included; we excluded surveillance specimens. MIC values were interpreted based upon CLSI M100-E34 breakpoints (Table 2A-1). Descriptive statistics were computed and compared between moderate-risk AmpC inducers (MRAC) versus low-risk AmpC inducers (LRAC). Results: 5,631 isolates were analyzed, with 3,778 (67.1%) identified as MRAC. Across all organisms, susceptibility rates for ceftriaxone, piperacillin-tazobactam, cefepime, and meropenem were 82.0%, 87.0%, 95.4%, and 98.7% respectively. Compared to LRAC, MRAC organisms demonstrated lower susceptibility to ceftriaxone (76.0% versus 94.2%) and piperacillin-tazobactam (81.3% versus 98.6%). Cefepime and meropenem demonstrated similar susceptibility rates between LRAC and MRAC. MIC90 for cefepime was 1 µg/ml for all species except E. cloacae (MIC90 4µg/ml). Conclusion: Between 2019-2024, 95.4% of our isolates demonstrated susceptibility to cefepime within our local health authority. Further research will correlate patient outcomes and establish MIC thresholds to guide routine testing and clinical use of cefepime.
- 11 March 2026
- Published by Microbiology Society
- p. 001122.v2
Open AccessAntimicrobial susceptibility and distribution trends among inducible AmpC-producing Enterobacterales at a regional health authority in British Columbia: a 5-year retrospective review
Introduction: Existing literature supports using cefepime as a carbapenem-sparing agent to treat AmpC-producing Enterobacterales infections. To characterize existing susceptibility trends, we conducted a 5-year retrospective study assessing minimum inhibitory concentration (MIC) distributions for ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem across Vancouver Island Health Authority (Vancouver Island, British Columbia, Canada). Methods: MIC data for AmpC isolates between November 2019 to October 2024 were retrieved (BD Epicenter™). Blood cultures, invasive specimens, urine and miscellaneous samples (e.g., respiratory, wounds) were included; we excluded surveillance specimens. MIC values were interpreted based upon CLSI M100-E34 breakpoints (Table 2A-1). Descriptive statistics were computed and compared between moderate-risk AmpC inducers (MRAC) versus low-risk AmpC inducers (LRAC). Results: 5,631 isolates were analyzed, with 3,778 (67.1%) identified as MRAC. Across all organisms, susceptibility rates for ceftriaxone, piperacillin-tazobactam, cefepime, and meropenem were 82.0%, 87.0%, 95.4%, and 98.7% respectively. Compared to LRAC, MRAC organisms demonstrated lower susceptibility to ceftriaxone (76.0% versus 94.2%) and piperacillin-tazobactam (81.3% versus 98.6%). Cefepime and meropenem demonstrated similar susceptibility rates between LRAC and MRAC. MIC90 for cefepime was 1 µg/ml for all species except E. cloacae (MIC90 4µg/ml). Conclusion: Between 2019-2024, 95.4% of our isolates demonstrated susceptibility to cefepime within our local health authority. Further research will correlate patient outcomes and establish MIC thresholds to guide routine testing and clinical use of cefepime.
- Open Access
- 30 September 2025
- Published by Microbiology Society
- p. 001122.v1
Antimicrobial susceptibility and distribution trends among AmpC-producing Enterobacterales at a regional health authority in British Columbia: a 5-year retrospective review
Introduction: Existing literature supports using cefepime as a carbapenem-sparing agent to treat AmpC-producing Enterobacterales infections. To characterize existing susceptibility trends, we conducted a 5-year retrospective study assessing minimum inhibitory concentration (MIC) distributions for ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem across Vancouver Island Health Authority (Vancouver Island, British Columbia, Canada). Methods: MIC data for AmpC isolates between November 2019 to October 2024 were retrieved (BD Epicenter™). Blood cultures, invasive specimens, urine and miscellaneous samples (e.g., respiratory, wounds) were included; we excluded surveillance specimens. MIC values were interpreted based upon CLSI M100-E34 breakpoints (Table 2A-1). Descriptive statistics were computed and compared between moderate-risk AmpC inducers (MRAC) versus low-risk AmpC inducers (LRAC). Results: 5,809 isolates were analyzed, with 3,646 (62.8%) identified as MRAC. Across all organisms, susceptibility rates for ceftriaxone, piperacillin-tazobactam, cefepime, and meropenem were 81.6%, 87.4%, 95.5%, and 98.7% respectively. Compared to LRAC, MRAC organisms demonstrated lower susceptibility to ceftriaxone (76.0% versus 91.1%) and piperacillin-tazobactam (81.5% versus 97.3%). Cefepime and meropenem demonstrated similar susceptibility rates between LRAC and MRAC. MIC90 for cefepime was 1 µg/ml for all species except E. cloacae (MIC90 4µg/ml). Conclusion: Between 2019-2024, 95.5% of our isolates demonstrated susceptibility to cefepime within our local health authority. Further research will correlate patient outcomes and establish MIC thresholds to guide routine testing and clinical use of cefepime.
- 30 September 2025
- Published by Microbiology Society
- p. 001122.v1
Open AccessAntimicrobial susceptibility and distribution trends among AmpC-producing Enterobacterales at a regional health authority in British Columbia: a 5-year retrospective review
Introduction: Existing literature supports using cefepime as a carbapenem-sparing agent to treat AmpC-producing Enterobacterales infections. To characterize existing susceptibility trends, we conducted a 5-year retrospective study assessing minimum inhibitory concentration (MIC) distributions for ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem across Vancouver Island Health Authority (Vancouver Island, British Columbia, Canada). Methods: MIC data for AmpC isolates between November 2019 to October 2024 were retrieved (BD Epicenter™). Blood cultures, invasive specimens, urine and miscellaneous samples (e.g., respiratory, wounds) were included; we excluded surveillance specimens. MIC values were interpreted based upon CLSI M100-E34 breakpoints (Table 2A-1). Descriptive statistics were computed and compared between moderate-risk AmpC inducers (MRAC) versus low-risk AmpC inducers (LRAC). Results: 5,809 isolates were analyzed, with 3,646 (62.8%) identified as MRAC. Across all organisms, susceptibility rates for ceftriaxone, piperacillin-tazobactam, cefepime, and meropenem were 81.6%, 87.4%, 95.5%, and 98.7% respectively. Compared to LRAC, MRAC organisms demonstrated lower susceptibility to ceftriaxone (76.0% versus 91.1%) and piperacillin-tazobactam (81.5% versus 97.3%). Cefepime and meropenem demonstrated similar susceptibility rates between LRAC and MRAC. MIC90 for cefepime was 1 µg/ml for all species except E. cloacae (MIC90 4µg/ml). Conclusion: Between 2019-2024, 95.5% of our isolates demonstrated susceptibility to cefepime within our local health authority. Further research will correlate patient outcomes and establish MIC thresholds to guide routine testing and clinical use of cefepime.
- Open Access
- 29 July 2025
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 113 (4) , 117034
Evaluation of the NG-Test® CTX-M MULTI lateral flow immunoassay and genomic discovery of a blaCTX-M-27 variant with a premature stop codon
- 29 July 2025
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 113 (4) , 117034
Open AccessEvaluation of the NG-Test® CTX-M MULTI lateral flow immunoassay and genomic discovery of a blaCTX-M-27 variant with a premature stop codon
- Open Access
- 16 June 2025
- Published by Elsevier in Clinical Microbiology Newsletter
- Vol. 52, 17-20
Vibrio cholerae cystitis following geothermal hot springs exposure in California
- 16 June 2025
- Published by Elsevier in Clinical Microbiology Newsletter
- Vol. 52, 17-20
Open AccessVibrio cholerae cystitis following geothermal hot springs exposure in California